ARC-2022 contains lidocaine in a 40 percent concentration in a clear, water-based gel that can be applied directly to painful skin areas of the body. The treatment showed effectiveness in a single-dose phase 1 pharmacokinetic study in adult patients with post-herpetic neuralgia.
Related Articles on Pain Management:
5 Ways to Safeguard Against Opioid Abuse and Diversion From Robert Saenz, CEO of Tulsa Pain Consultants
Epidural Steroid Injections Increase Blood Glucose Levels in Patients With Diabetes
NeurogesX Appoints Ronald Martell President and Chief Executive Officer
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
